Skip to main content

Nasal vaccine suspends peanut allergies in mice. Could humans be next?

Imagine a vaccine that can “turn off” peanut allergies, an allergic reaction which affects more than 3 million people in the United States alone. Thanks to research carried out at Mary H. Weiser Food Allergy Center at the University of Michigan, such a dream might become a reality.

Researchers at the institution have developed a special nasal vaccine, and demonstrated its efficacy in mice. The vaccine is a nanoemulsion capable of increasing the body’s natural immune response. After just a few monthly doses of the vaccine, mice were temporarily protected from allergic reactions after peanut exposure. This immunization against the reaction continued for two weeks after the final dose of vaccine had been administered. The exact duration is still being investigated.

Recommended Videos

“Our group is working towards the development of vaccines as a safe and long-lasting immunotherapies to treat food allergy,” Jessica O’Konek, a research investigator at the Mary H. Weiser Food Allergy Center, told Digital Trends. “We studied our experimental vaccine in mouse models of peanut allergy and found that three doses of the vaccine changed the immune responses to peanut, suppressing the components of the response that are known to result in allergic reactions. Importantly, mice that received the vaccine had significantly less severe reactions to peanut exposure compared to mice that received the placebo. These results are exciting because they demonstrate that just three doses of a vaccine can confer protection from allergic reactions to peanut.”

While this work has currently only been conducted with mice, it is a potentially significant advance which may one day be carried over to humans. Interestingly, mice with an allergic response to peanuts exhibit similar symptoms to humans, including itchy skin and difficulty breathing.

“We are currently testing how long the protection induced by the vaccine lasts, as well as expanding our studies to include other food allergens,” O’Konek continued. “We are also further investigating the mechanisms by which this vaccine works, and are hopeful that we will move this forward towards clinical trials in humans.”

A paper describing the work, “Nanoemulsion adjuvant-driven redirection of TH2 immunity inhibits allergic reactions in murine models of peanut allergy,” was recently published in the Journal of Allergy and Clinical Immunology.

Luke Dormehl
Former Digital Trends Contributor
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Waymo, Nexar present AI-based study to protect ‘vulnerable’ road users
waymo data vulnerable road users ml still  1 ea18c3

Robotaxi operator Waymo says its partnership with Nexar, a machine-learning tech firm dedicated to improving road safety, has yielded the largest dataset of its kind in the U.S., which will help inform the driving of its own automated vehicles.

As part of its latest research with Nexar, Waymo has reconstructed hundreds of crashes involving what it calls ‘vulnerable road users’ (VRUs), such as pedestrians walking through crosswalks, biyclists in city streets, or high-speed motorcycle riders on highways.

Read more
Rivian, VW venture kicks off next-gen platform for R1, Scout EVs
Rivian R2, R3, and R3X

The big challenge for Rivian, the EV maker known for its innovative electric and software systems, has long been how to reach the next stage of growth.

That stage came within reach in June, when the California-based company and Volkswagen announced a joint venture involving a $5 billion injection from the German automaker.

Read more
Hyundai teases Ioniq 9 electric SUV’s interior ahead of expected launch
hyundai ioniq 9 teaser launch 63892 image1hyundaimotorpresentsfirstlookationiq9embarkingonaneweraofspaciousevdesign

The Ioniq 9, the much anticipated three-row, electric SUV from Hyundai, will be officially unveiled at the Los Angeles Auto Show next week.

Selected by Newsweek as one of America’s most anticipated new vehicles of 2025, the Ioniq 9 recently had its name changed from the Ioniq 7, which would have numerically followed the popular Ioniq 6, to signal the SUV as Hyundai’s new flagship EV model.

Read more